RecruitingPhase 1NCT07422298

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

A Phase 1, Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization in Healthy Participants

Sponsor

Bristol-Myers Squibb

Enrollment

32 participants

Start Date

Feb 19, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Volunteers

Summary

The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria3

Female individuals not of childbearing potential and males.
Healthy as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments.
to 55 years of age, inclusive, at the time of signing the informed consent with a BMI 18.0 to 32.0 kg/m2, inclusive.

Interested in this trial?

Get notified about updates and connect with the research team.